Joel Beatty
Stock Analyst at Baird
(4.23)
# 412
Out of 4,858 analysts
201
Total ratings
44.44%
Success rate
17.46%
Average return
Main Sectors:
Stocks Rated by Joel Beatty
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ELF e.l.f. Beauty | Maintains: Outperform | $110 → $145 | $124.52 | +16.45% | 6 | Jun 6, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Outperform | $28 → $31 | $22.30 | +39.01% | 4 | May 19, 2025 | |
| NGNE Neurogene | Downgrades: Neutral | $38 → $24 | $20.92 | +14.72% | 3 | May 16, 2025 | |
| EDIT Editas Medicine | Maintains: Outperform | $8 → $4 | $2.03 | +97.04% | 4 | May 13, 2025 | |
| DNTH Dianthus Therapeutics | Maintains: Outperform | $58 → $50 | $18.12 | +175.94% | 2 | May 13, 2025 | |
| ARGX argenx SE | Upgrades: Outperform | $680 | $575.55 | +18.15% | 7 | May 13, 2025 | |
| DNLI Denali Therapeutics | Maintains: Outperform | $30 → $29 | $15.17 | +91.17% | 2 | May 8, 2025 | |
| PTCT PTC Therapeutics | Maintains: Outperform | $70 → $66 | $50.79 | +29.95% | 15 | May 7, 2025 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Outperform | $167 → $155 | $110.50 | +40.27% | 4 | May 7, 2025 | |
| COGT Cogent Biosciences | Maintains: Neutral | $8 → $7 | $7.26 | -3.58% | 5 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $160 → $162 | $108.08 | +49.89% | 5 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $38 → $41 | $31.20 | +31.41% | 3 | May 2, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $10 | $3.10 | +222.58% | 2 | Mar 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $27 → $16 | $7.40 | +116.22% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $16 | $4.58 | +249.34% | 2 | Mar 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $117 → $73 | $44.60 | +63.70% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $28 → $32 | $25.41 | +25.93% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $75 | $27.75 | +170.27% | 1 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $3 → $11 | $5.42 | +102.95% | 4 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $6 → $7 | $1.85 | +278.38% | 5 | Nov 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $72 → $65 | $57.16 | +13.72% | 5 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $13 → $9 | $6.77 | +32.94% | 4 | Oct 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $112 → $127 | $127.95 | -0.74% | 3 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $68 → $72 | $37.51 | +91.95% | 4 | May 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $45 → $20 | $0.34 | +5,715.64% | 3 | May 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $4.5 | $1.54 | +192.21% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $25 | $12.63 | +98.02% | 3 | Apr 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $9 | $0.44 | +1,964.69% | 2 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $32 → $28 | $10.90 | +156.88% | 2 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $16 | $8.09 | +97.78% | 1 | Jun 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $1.25 | $2.91 | -57.04% | 2 | May 2, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $44 | $1.46 | +2,913.70% | 3 | Apr 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $60 → $58 | $16.74 | +246.48% | 6 | Feb 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $18 → $24 | $21.92 | +9.49% | 2 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $18 | $12.44 | +44.75% | 3 | Nov 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $9 → $6 | $3.87 | +55.24% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $46 → $31 | $1.27 | +2,340.94% | 3 | Jun 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $36 → $28 | $5.25 | +433.33% | 2 | Mar 3, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $175 | $298.58 | -41.39% | 2 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $14 | $4.58 | +205.68% | 8 | Jan 14, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $108 | $37.81 | +185.64% | 10 | Jan 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $80 → $78 | $36.17 | +115.65% | 3 | Aug 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $140 → $100 | $8.83 | +1,032.50% | 2 | Apr 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $120 | $13.25 | +805.66% | 14 | Apr 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $480 → $450 | $3.21 | +13,940.56% | 2 | Mar 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | n/a | $1.21 | - | 12 | Mar 17, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $19 → $15 | $7.09 | +111.57% | 11 | Sep 24, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $240 → $120 | $0.71 | +16,737.38% | 2 | Aug 17, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $19 | $6.92 | +174.57% | 3 | Nov 10, 2017 |
e.l.f. Beauty
Jun 6, 2025
Maintains: Outperform
Price Target: $110 → $145
Current: $124.52
Upside: +16.45%
ACADIA Pharmaceuticals
May 19, 2025
Maintains: Outperform
Price Target: $28 → $31
Current: $22.30
Upside: +39.01%
Neurogene
May 16, 2025
Downgrades: Neutral
Price Target: $38 → $24
Current: $20.92
Upside: +14.72%
Editas Medicine
May 13, 2025
Maintains: Outperform
Price Target: $8 → $4
Current: $2.03
Upside: +97.04%
Dianthus Therapeutics
May 13, 2025
Maintains: Outperform
Price Target: $58 → $50
Current: $18.12
Upside: +175.94%
argenx SE
May 13, 2025
Upgrades: Outperform
Price Target: $680
Current: $575.55
Upside: +18.15%
Denali Therapeutics
May 8, 2025
Maintains: Outperform
Price Target: $30 → $29
Current: $15.17
Upside: +91.17%
PTC Therapeutics
May 7, 2025
Maintains: Outperform
Price Target: $70 → $66
Current: $50.79
Upside: +29.95%
Jazz Pharmaceuticals
May 7, 2025
Maintains: Outperform
Price Target: $167 → $155
Current: $110.50
Upside: +40.27%
Cogent Biosciences
May 7, 2025
Maintains: Neutral
Price Target: $8 → $7
Current: $7.26
Upside: -3.58%
May 6, 2025
Maintains: Outperform
Price Target: $160 → $162
Current: $108.08
Upside: +49.89%
May 2, 2025
Maintains: Outperform
Price Target: $38 → $41
Current: $31.20
Upside: +31.41%
Mar 25, 2025
Maintains: Outperform
Price Target: $13 → $10
Current: $3.10
Upside: +222.58%
Mar 7, 2025
Maintains: Outperform
Price Target: $27 → $16
Current: $7.40
Upside: +116.22%
Mar 7, 2025
Maintains: Outperform
Price Target: $32 → $16
Current: $4.58
Upside: +249.34%
Mar 3, 2025
Maintains: Outperform
Price Target: $117 → $73
Current: $44.60
Upside: +63.70%
Mar 3, 2025
Maintains: Outperform
Price Target: $28 → $32
Current: $25.41
Upside: +25.93%
Nov 25, 2024
Initiates: Outperform
Price Target: $75
Current: $27.75
Upside: +170.27%
Nov 18, 2024
Upgrades: Outperform
Price Target: $3 → $11
Current: $5.42
Upside: +102.95%
Nov 15, 2024
Maintains: Outperform
Price Target: $6 → $7
Current: $1.85
Upside: +278.38%
Oct 30, 2024
Maintains: Neutral
Price Target: $72 → $65
Current: $57.16
Upside: +13.72%
Oct 9, 2024
Maintains: Neutral
Price Target: $13 → $9
Current: $6.77
Upside: +32.94%
Aug 2, 2024
Maintains: Outperform
Price Target: $112 → $127
Current: $127.95
Upside: -0.74%
May 31, 2024
Maintains: Outperform
Price Target: $68 → $72
Current: $37.51
Upside: +91.95%
May 15, 2024
Maintains: Outperform
Price Target: $45 → $20
Current: $0.34
Upside: +5,715.64%
Apr 30, 2024
Downgrades: Neutral
Price Target: $4.5
Current: $1.54
Upside: +192.21%
Apr 11, 2024
Maintains: Outperform
Price Target: $24 → $25
Current: $12.63
Upside: +98.02%
Mar 19, 2024
Maintains: Outperform
Price Target: $11 → $9
Current: $0.44
Upside: +1,964.69%
Oct 3, 2023
Maintains: Outperform
Price Target: $32 → $28
Current: $10.90
Upside: +156.88%
Jun 1, 2023
Initiates: Outperform
Price Target: $16
Current: $8.09
Upside: +97.78%
May 2, 2023
Maintains: Outperform
Price Target: $4 → $1.25
Current: $2.91
Upside: -57.04%
Apr 13, 2023
Initiates: Outperform
Price Target: $44
Current: $1.46
Upside: +2,913.70%
Feb 7, 2023
Maintains: Outperform
Price Target: $60 → $58
Current: $16.74
Upside: +246.48%
Nov 18, 2022
Maintains: Outperform
Price Target: $18 → $24
Current: $21.92
Upside: +9.49%
Nov 10, 2022
Downgrades: Underperform
Price Target: $18
Current: $12.44
Upside: +44.75%
Aug 29, 2022
Maintains: Outperform
Price Target: $9 → $6
Current: $3.87
Upside: +55.24%
Jun 1, 2022
Maintains: Outperform
Price Target: $46 → $31
Current: $1.27
Upside: +2,340.94%
Mar 3, 2022
Upgrades: Neutral
Price Target: $36 → $28
Current: $5.25
Upside: +433.33%
Feb 12, 2021
Downgrades: Neutral
Price Target: $170 → $175
Current: $298.58
Upside: -41.39%
Jan 14, 2021
Downgrades: Neutral
Price Target: $14
Current: $4.58
Upside: +205.68%
Jan 12, 2021
Downgrades: Neutral
Price Target: $108
Current: $37.81
Upside: +185.64%
Aug 10, 2020
Maintains: Buy
Price Target: $80 → $78
Current: $36.17
Upside: +115.65%
Apr 6, 2020
Maintains: Buy
Price Target: $140 → $100
Current: $8.83
Upside: +1,032.50%
Apr 1, 2020
Maintains: Buy
Price Target: $480 → $120
Current: $13.25
Upside: +805.66%
Mar 26, 2020
Maintains: Buy
Price Target: $480 → $450
Current: $3.21
Upside: +13,940.56%
Mar 17, 2020
Upgrades: Buy
Price Target: n/a
Current: $1.21
Upside: -
Sep 24, 2019
Maintains: Buy
Price Target: $19 → $15
Current: $7.09
Upside: +111.57%
Aug 17, 2018
Maintains: Neutral
Price Target: $240 → $120
Current: $0.71
Upside: +16,737.38%
Nov 10, 2017
Maintains: Buy
Price Target: $15 → $19
Current: $6.92
Upside: +174.57%